JP7089141B2 - 新規なｊａｋ１選択的阻害剤およびその使用 - Google Patents
新規なｊａｋ１選択的阻害剤およびその使用 Download PDFInfo
- Publication number
- JP7089141B2 JP7089141B2 JP2019517991A JP2019517991A JP7089141B2 JP 7089141 B2 JP7089141 B2 JP 7089141B2 JP 2019517991 A JP2019517991 A JP 2019517991A JP 2019517991 A JP2019517991 A JP 2019517991A JP 7089141 B2 JP7089141 B2 JP 7089141B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- nrr
- formula
- imidazole
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662403660P | 2016-10-03 | 2016-10-03 | |
| US62/403,660 | 2016-10-03 | ||
| PCT/US2017/054668 WO2018067422A1 (en) | 2016-10-03 | 2017-09-30 | Novel jak1 selective inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019537559A JP2019537559A (ja) | 2019-12-26 |
| JP2019537559A5 JP2019537559A5 (enExample) | 2021-03-04 |
| JP7089141B2 true JP7089141B2 (ja) | 2022-06-22 |
Family
ID=61831161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517991A Active JP7089141B2 (ja) | 2016-10-03 | 2017-09-30 | 新規なｊａｋ１選択的阻害剤およびその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | USRE49834E1 (enExample) |
| EP (1) | EP3509591B1 (enExample) |
| JP (1) | JP7089141B2 (enExample) |
| KR (1) | KR102399848B1 (enExample) |
| CN (2) | CN113214278B (enExample) |
| AU (3) | AU2017339417C1 (enExample) |
| DK (1) | DK3509591T3 (enExample) |
| EA (1) | EA201990523A1 (enExample) |
| ES (1) | ES2901216T3 (enExample) |
| HK (1) | HK1253040A1 (enExample) |
| HR (1) | HRP20211965T1 (enExample) |
| HU (1) | HUE058120T2 (enExample) |
| IL (3) | IL265358B (enExample) |
| MX (1) | MX390005B (enExample) |
| NZ (1) | NZ751284A (enExample) |
| PL (1) | PL3509591T3 (enExample) |
| PT (1) | PT3509591T (enExample) |
| RS (1) | RS62695B1 (enExample) |
| WO (1) | WO2018067422A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3509591T3 (da) | 2016-10-03 | 2021-12-20 | Highlightll Pharmaceutical Hainan Co Ltd | Nye jak1-selektive inhibitorer og anvendelser deraf |
| RU2019125177A (ru) * | 2017-01-11 | 2021-02-15 | Лео Фарма А/С | Новые производные амино-имидазопиридина в качестве ингибиторов янус-киназы и их фармацевтическое применение |
| IL282643B2 (en) * | 2018-10-31 | 2025-08-01 | Incyte Corp | A selective jak1 inhibitor for use in a method of treating hematological disease |
| JP2022524997A (ja) | 2019-03-05 | 2022-05-11 | インサイト・コーポレイション | 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤 |
| JP2022526301A (ja) | 2019-03-19 | 2022-05-24 | インサイト・コーポレイション | 尋常性白斑のバイオマーカー |
| JP7628967B2 (ja) * | 2019-06-06 | 2025-02-12 | ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド | フロイミダゾピリジン化合物、多形物質および塩の多形物質の合成方法 |
| CN113906035B (zh) | 2019-06-06 | 2023-11-10 | 杭州高光制药有限公司 | 呋喃并咪唑并吡啶类化合物的合成方法、呋喃并咪唑并吡啶类化合物的晶型及其盐的晶型 |
| CN115803317B (zh) | 2020-05-19 | 2025-07-15 | 拜耳作物科学股份公司 | 作为杀真菌化合物的氮杂双环(硫代)酰胺 |
| JP7729845B2 (ja) | 2020-06-10 | 2025-08-26 | バイエル、アクチエンゲゼルシャフト | 新規殺菌剤としてのアザビシクリル置換複素環 |
| WO2022260945A1 (en) * | 2021-06-07 | 2022-12-15 | The Regents Of The University Of California | Compositions and methods for treating celiac disease |
| JP2024543198A (ja) * | 2021-09-13 | 2024-11-19 | ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド | 中枢神経障害を治療する方法 |
| CN114213424B (zh) | 2021-12-30 | 2023-05-26 | 杭州高光制药有限公司 | 一种呋喃[3，2-b]并吡啶衍生物的合成方法 |
| WO2025224600A1 (en) * | 2024-04-21 | 2025-10-30 | Biohaven Therapeutics Ltd. | Treatment of alpha-synucleinopathies and neuroprotection |
| WO2025248468A1 (en) | 2024-05-28 | 2025-12-04 | Biohaven Therapeutics Ltd. | Use of tyk2/jak1 inhibitors to treat amyloid-related imaging abnormalities (aria) |
| WO2026002028A1 (zh) * | 2024-06-26 | 2026-01-02 | 杭州多域生物技术有限公司 | 稠杂芳环类化合物、其药物组合物及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015535288A (ja) | 2012-11-01 | 2015-12-10 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害薬としての三環式縮合チオフェン誘導体 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| ATE66143T1 (de) | 1985-01-11 | 1991-08-15 | Abbott Lab | Feste zubereitung mit langsamer freisetzung. |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| CA2338780C (en) | 1998-07-28 | 2007-01-02 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing medicinal substance at targeted site in intestine |
| JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | １ｈ―イミダゾピリジン誘導体 |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US6800663B2 (en) | 2002-10-18 | 2004-10-05 | Alkermes Controlled Therapeutics Inc. Ii, | Crosslinked hydrogel copolymers |
| EP1720855A4 (en) | 2004-03-02 | 2008-12-17 | Smithkline Beecham Corp | HEMMER OF ACT ACTIVITY |
| CN101277965A (zh) * | 2005-08-04 | 2008-10-01 | 西特里斯药业公司 | 作为SIRTUIN调节化合物的咪唑并[2,1-b]噻唑衍生物 |
| JP2013505965A (ja) * | 2009-09-29 | 2013-02-21 | エックスカバリー ホールディング カンパニー エルエルシー | Ｐｉ３ｋ（デルタ）選択的阻害剤 |
| WO2012022045A1 (en) * | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| EP2624698A4 (en) | 2010-10-08 | 2014-10-08 | Abbvie Inc | Furo [3,2-D] PYRIMIDINE COMPOUNDS |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| RU2632870C2 (ru) | 2011-08-12 | 2017-10-11 | Ниссан Кемикал Индастриз, Лтд. | Трициклические гетероциклические соединения и ингибиторы jak |
| US20150118229A1 (en) | 2013-10-24 | 2015-04-30 | Abbvie Inc. | Jak1 selective inhibitor and uses thereof |
| JP2017514832A (ja) | 2014-04-30 | 2017-06-08 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ１抑制剤を調製する方法及びその新しい形態 |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| DK3509591T3 (da) | 2016-10-03 | 2021-12-20 | Highlightll Pharmaceutical Hainan Co Ltd | Nye jak1-selektive inhibitorer og anvendelser deraf |
-
2017
- 2017-09-30 DK DK17858944.6T patent/DK3509591T3/da active
- 2017-09-30 US US17/526,799 patent/USRE49834E1/en active Active
- 2017-09-30 ES ES17858944T patent/ES2901216T3/es active Active
- 2017-09-30 AU AU2017339417A patent/AU2017339417C1/en active Active
- 2017-09-30 PL PL17858944T patent/PL3509591T3/pl unknown
- 2017-09-30 MX MX2019003649A patent/MX390005B/es unknown
- 2017-09-30 CN CN202110514751.5A patent/CN113214278B/zh active Active
- 2017-09-30 RS RS20211521A patent/RS62695B1/sr unknown
- 2017-09-30 HR HRP20211965TT patent/HRP20211965T1/hr unknown
- 2017-09-30 PT PT178589446T patent/PT3509591T/pt unknown
- 2017-09-30 US US16/333,994 patent/US10738060B2/en not_active Ceased
- 2017-09-30 EA EA201990523A patent/EA201990523A1/ru unknown
- 2017-09-30 EP EP17858944.6A patent/EP3509591B1/en active Active
- 2017-09-30 HU HUE17858944A patent/HUE058120T2/hu unknown
- 2017-09-30 CN CN201780004442.5A patent/CN108366994B/zh active Active
- 2017-09-30 WO PCT/US2017/054668 patent/WO2018067422A1/en not_active Ceased
- 2017-09-30 JP JP2019517991A patent/JP7089141B2/ja active Active
- 2017-09-30 HK HK18112420.5A patent/HK1253040A1/zh unknown
- 2017-09-30 NZ NZ751284A patent/NZ751284A/en unknown
- 2017-09-30 KR KR1020197009016A patent/KR102399848B1/ko active Active
-
2019
- 2019-03-13 IL IL265358A patent/IL265358B/en unknown
-
2022
- 2022-02-17 AU AU2022201058A patent/AU2022201058B2/en active Active
- 2022-02-17 AU AU2022201061A patent/AU2022201061B2/en active Active
- 2022-03-10 IL IL291265A patent/IL291265B2/en unknown
- 2022-03-10 IL IL291267A patent/IL291267B2/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015535288A (ja) | 2012-11-01 | 2015-12-10 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害薬としての三環式縮合チオフェン誘導体 |
Non-Patent Citations (1)
| Title |
|---|
| The Organic Chemistry of Drug Design and Drug Action ，2nd Edition，2004年，pp.29-34 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7089141B2 (ja) | 新規なｊａｋ１選択的阻害剤およびその使用 | |
| JP7248256B2 (ja) | Ｊａｋキナーゼ阻害剤及びその調製方法、並びにその医薬分野での使用 | |
| EP3555097B1 (en) | Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of janus kinases | |
| JP7085566B2 (ja) | アポトーシス誘発剤 | |
| US10961228B2 (en) | JAK1 selective inhibitors | |
| EP4520329A2 (en) | Treatment of respiratory diseases with amino acid compounds | |
| CN113677346A (zh) | 周期蛋白依赖性激酶7(cdk7)的抑制剂 | |
| AU2021389180A9 (en) | Heteroaryl carboxamide compound | |
| TW202304880A (zh) | Ｎ２－苯基嘧啶－２，４－二胺化合物及其製備方法及使用方法 | |
| CN108419436B (zh) | 一种取代的吡嗪甲酰胺类化合物及包含该化合物的组合物及其用途 | |
| CA3039178C (en) | Novel jak1 selective inhibitors and uses thereof | |
| HK40047523B (en) | Novel jak1 selective inhibitors and uses thereof | |
| HK40047523A (en) | Novel jak1 selective inhibitors and uses thereof | |
| EA040948B1 (ru) | Селективные ингибиторы jak1 и их применение | |
| HK40004735B (en) | Novel jak1 selective inhibitors and uses thereof | |
| BR112019005969B1 (pt) | Inibidores seletivos de jak1 e usos dos mesmos | |
| HK40098388A (en) | Jak1 selective inhibitors | |
| EA047776B1 (ru) | Соединение гетероарилкарбоксамида | |
| HK40065050A (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| HK40014753A (en) | Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of janus kinases | |
| HK40014753B (en) | Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of janus kinases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200729 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210119 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20210326 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210326 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210610 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210615 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210913 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211005 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211209 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220405 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20220426 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220428 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220426 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7089141 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |